The bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.
Ceeable, a web-based, mobile digital technology designed to detect early-stage eye diseases—an innovation that can help shape 21st century medicine—was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.
After speaking at last week’s Republican National Convention in Cleveland, New Mexico OD Lisa Shin says more optometrists should get involved on a national level to keep optometry’s agenda at the forefront.
The pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.